GCP
SNDX icon

GSA Capital Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

GSA Capital Partners’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Buy
62,775
+14,221
+29% +$296K 0.09% 330
2026
Q1 		$1.13M Buy
48,554
+26,031
+116% +$566K 0.07% 423
2025
Q4 		$473K Buy
22,523
+5,615
+33% +$98K 0.04% 848
2025
Q3 		$260K Sell
16,908
-522
-3% -$6.83K 0.02% 1283
2025
Q2 		$163K Sell
17,430
-69,854
-80% -$769K 0.01% 1550
2025
Q1 		$1.07M Buy
87,284
+50,427
+137% +$711K 0.1% 314
2024
Q4 		$487K Buy
+36,857
New +$631K 0.04% 913
2024
Q1 		– Sell
-24,659
Closed -$533K – 1942
2023
Q4 		$533K Buy
+24,659
New +$379K 0.04% 753
2022
Q3 		– Sell
-11,542
Closed -$222K – 1832
2022
Q2 		$222K Sell
11,542
-31,758
-73% -$529K 0.03% 1025
2022
Q1 		$753K Buy
+43,300
New +$729K 0.1% 304
2021
Q1 		– Sell
-23,958
Closed -$533K – 1468
2020
Q4 		$533K Sell
23,958
-13,462
-36% -$279K 0.09% 390
2020
Q3 		$552K Buy
+37,420
New +$570K 0.09% 336
2020
Q1 		– Sell
-23,041
Closed -$202K – 1519
2019
Q4 		$202K Buy
+23,041
New +$169K 0.02% 1255
2019
Q3 		– Sell
-24,550
Closed -$229K – 1684
2019
Q2 		$229K Buy
24,550
+9,227
+60% +$67.3K 0.03% 1171
2019
Q1 		$80K Buy
+15,323
New +$87.4K 0.01% 1344
2018
Q3 		– Sell
-52,400
Closed -$368K – 1878
2018
Q2 		$368K Buy
+52,400
New +$514K 0.02% 1298

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

GSA Capital Partners's SNDX Position: Q2 2026 in Review

GSA Capital Partners increased its Syndax Pharmaceuticals (SNDX) stake by 29% in Q2 2026, buying an estimated $296K and bringing the position to 62,775 shares worth $1.37M. The position accounts for 0.09% of the portfolio, ranked #330.

GSA Capital Partners first reported a position in SNDX in Q2 2018 and has held it in 16 quarters since. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • GSA Capital Partners held 62,775 shares of Syndax Pharmaceuticals worth $1.37M as of Q2 2026.
  • GSA Capital Partners bought 14,221 Syndax Pharmaceuticals shares in Q2 2026, an estimated $296K.
  • Syndax Pharmaceuticals made up 0.09% of GSA Capital Partners's portfolio in Q2 2026, its #330 holding.
  • GSA Capital Partners first reported a position in Syndax Pharmaceuticals in Q2 2018 and has held it in 16 quarters since.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.